Results 11 to 20 of about 31,287 (242)

Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. [PDF]

PLoS ONE, 2017
Treatment of patients with diffuse large B cell lymphoma (DLBCL) includes rituximab, an anti-CD20 monoclonal antibody (mAb). Insufficient tumor targeting might cause therapy failure. Tumor uptake of 89Zirconium (89Zr)-mAb is a potential imaging biomarker
Yvonne W S Jauw, Josée M Zijlstra, Daphne de Jong, Danielle J Vugts, Sonja Zweegman, Otto S Hoekstra, Guus A M S van Dongen, Marc C Huisman   +7 more
doaj   +2 more sources

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial [PDF]

Journal of Hematology & Oncology, 2012
Background The randomized phase 3 LYM3001 trial in relapsed follicular lymphoma (FL) demonstrated higher overall (ORR) and complete response (CR) rates and prolonged progression-free survival (PFS) with bortezomib-rituximab versus rituximab.
Zinzani Pier, Khuageva Nuriet K, Wang Huaqing, Garicochea Bernardo, Walewski Jan, Van Hoof Achiel, Soubeyran Pierre, Caballero Dolores, Buckstein Rena, Esseltine Dixie-Lee, Theocharous Panteli, Enny Christopher, Zhu Eugene, Elsayed Yusri A, Coiffier Bertrand   +14 more
doaj   +2 more sources

Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness

ClinicoEconomics and Outcomes Research, 2010
Firas Badin, John HayslipUniversity of Kentucky, Markey Cancer Center, Lexington, KY, USAAbstract: Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent
Firas Badin, John Hayslip
doaj   +3 more sources

Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab [PDF]

, 2009
In neuromyelitis optica (NMO), the monoclonal B-cell antibody rituximab is a therapeutic option. Little is known about the course of NMO and the safety of rituximab during pregnancy.
Hohlfeld, R., Pellkofer, H. L., Suessmair, C., Schulze, A., Kümpfel, Tania   +4 more
core   +1 more source

Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study [PDF]

, 2021
PURPOSE: The double-blind, randomized, placebo-controlled phase III iNNOVATE study showed sustained efficacy of ibrutinib-rituximab in Waldenström's macroglobulinemia (WM). Here, we present the final analysis from iNNOVATE.
Matous, Jeffrey V., Trotman, Judith, Varettoni, Marzia, Herbaux, Charles, Heffner, Leonard T., Tam, Constantine S., Hauns, Bernhard, Treon, Steven P., Buske, Christian, Tedeschi, Alessandra, García-Sanz, Ramón, MacDonald, David, Palomba, M. Lia, Arango-Hisijara, Israel, Mahe, Beatrice, Leblond, Veronique, Dimopoulos, Meletios A., Shustik, Chaim, Kastritis, Efstathios, Ping, Jerry   +19 more
core   +1 more source

Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma

Journal of Hematology & Oncology, 2022
Inevitable relapses remain as the major therapeutic challenge in patients with mantle cell lymphoma (MCL) despite FDA approval of multiple targeted therapies and immunotherapies.
Vivian Changying Jiang, Yang Liu, Alexa Jordan, Angela Leeming, Joseph McIntosh, Shengjian Huang, Rongjia Zhang, Qingsong Cai, Zhihong Chen, Yijing Li, Yuxuan Che, Lei Nie, Ingrid Karlsson, Linda Mårtensson, Mathilda Kovacek, Ingrid Teige, Björn Frendéus, Michael Wang   +17 more
doaj   +1 more source

Rituximab

Indian Pediatrics, 2011
Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cell death by antibody dependant cell-mediated cytotoxicity, complement mediated cytotoxicity and apoptosis. It leads to rapid and sustained depletion of B cells.
Anupama, Borker, Narendra, Choudhary
openaire   +2 more sources

Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy

American Journal of Ophthalmology Case Reports, 2016
Purpose: To describe the effect of rituximab on full-field electroretinography (ERG) in a patient with nonparaneoplastic autoimmune retinopathy (npAIR). Observations: A 58-year-old male patient with visual complaints, positive anti-retinal antibodies and
Gunay Uludag, Sumru Onal, Serra Arf, Isil Sayman Muslubas, Fatih Selcukbiricik, Aylin Koc Akbay, Nil Molinas Mandel   +6 more
doaj   +1 more source

Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia

Haematologica, 2013
Rituximab is an effective treatment for autoimmune cytopenias associated with chronic lymphocytic leukemia. Despite the incorporation of rituximab into fludarabine-based chemotherapy regimens, the incidence of autoimmune cytopenias has remained high ...
Clifton C. Mo, Ndegwa Njuguna, Paul V. Beum, Margaret A. Lindorfer, Berengere Vire, Elinor Lee, Gerald Marti, Wyndham H Wilson, Ronald P. Taylor, Adrian Wiestner   +9 more
doaj   +1 more source

Rituximab in dermatology

Actas Dermo-Sifiliográficas (English Edition), 2013
Rituximab was introduced into clinical practice as a medication with considerable potential. Its use in patients with B-cell lymphoma and rheumatoid arthritis revealed numerous indications in autoimmune diseases, many of which involve the skin, thus requiring dermatologists to become familiar with both the characteristics of anti-CD20 antibodies and ...
A, España, E, Ornilla, C, Panizo
openaire   +2 more sources